Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The dementias.

Karen Ritchie1, Simon Lovestone

  • 1Institut National de la Santé et de la Recherche Médicale, EMI 99-30, Hôpital La Colombière, Montpellier, France. ritchie@montp.inserm.fr

Lancet (London, England)
|December 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost utility and cost-effectiveness of the APPLE-Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce: economic evaluation embedded within a randomised controlled trial.

Age and ageing·2026
Same author

Diabetes, impaired fasting glucose, and cognitive trajectories: a multi-cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Disturbing dreams and dementia incidence across diverse cohort studies: A COSMIC collaboration study.

Psychiatry and clinical neurosciences·2026
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Dementia impacts 5% of older adults, with unknown reasons for higher rates in women. Research advances understanding and treatment for various dementia types, focusing on neurobiology and risk factors.

Area of Science:

  • Neurology
  • Geriatrics
  • Neuroscience

Background:

  • Dementia affects approximately 5% of individuals over 65.
  • Unexplained gender predominance and cultural variations exist.
  • Current classifications of dementia types (e.g., Alzheimer's, Lewy body) are being re-evaluated due to shared neuropathology.

Purpose of the Study:

  • To review current understanding of dementia causes and neuropathology.
  • To explore emerging diagnostic and therapeutic strategies.
  • To highlight challenges in disease management and long-term care.

Main Methods:

  • Review of neurochemical and neurobiological research.
  • Analysis of functional imaging for biomarker identification.
  • Examination of genetic testing and counselling advancements.

Related Experiment Videos

Main Results:

  • Advances in understanding dementia causes through neurobiology.
  • Identification of potential biomarkers via functional imaging.
  • Development of treatment approaches targeting neurotransmitters, amyloid, and risk factors (hypertension, depression, hypolipidaemia).

Conclusions:

  • Molecular diagnostics and genetic counselling are useful for early-onset dementia but not late-onset.
  • Fundamental research is progressing towards biological treatments.
  • Significant needs remain in dementia disease management and long-term care models.